REGULATORY SCIENCES
- Guidance on nonclinical and clinical regulatory strategy on all biopharmaceutical products
- Expert advice on orphan drugs designation, break-through therapy, accelerated approval, ANDA and 505(b)(2) submissions
- Conduct scientific and business centric due diligence assessments (on-site and/or electronic) of new drugs and acquisition